< Back to situations

Get alerts on this situation

We’ll email you as it develops, and you can follow the whole thread from day one.

Unsubscribe anytime.

[SITUATION] · [ACTIVE]

4 clusters · 51 sources · 10 days · First seen 11 days ago · Last updated 2 days ago

Categories: HEALTH

Merck Lipfendra oral PCSK9 approval

Entities: Lipfendra (enlicitide) · Michael Davis · PCSK9 protein · Merck & Co (MSD) · U.S. Food and Drug Administration

Overview

The U.S. Food and Drug Administration has confirmed approval of Merck’s Lipfendra (enlicitil‑de), the first once‑daily oral tablet that inhibits the PCSK9 protein. Clinical trials in more than 3,200 adults with primary hypercholesterolemia—including patients on high‑dose statins and those with heterozygous familial hypercholesterolemia—showed average LDL‑cholesterol reductions of about 56 % and up to 59 % in the heterozygous subgroup after 24–28 weeks, with peak reductions near 60 % over six months. A later analysis encompassing over 19,000 participants on statins and lifestyle measures confirmed a similar magnitude of LDL reduction and a favorable safety profile with few side effects.

Safety outcomes were comparable to placebo; the most frequent adverse events were dizziness and diarrhea. Lipfendra does not affect lipoprotein(a) levels. Priced at roughly $315 for a 30‑day supply—considerably lower than the $500‑$600 monthly cost of injectable PCSK9 biologics—the oral tablet is expected to improve adherence and broaden access for the estimated six million Americans eligible for PCSK9‑targeted therapy. It is intended as an adjunct to diet, exercise, and statin therapy for patients whose LDL remains elevated despite statins or who cannot tolerate statins, and is taken on an empty stomach.

The approval expands treatment options beyond statins and injectables, and Merck plans to seek regulatory clearance in other markets such as Brazil.

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 4 SOURCES] The FDA approved enlicitide, the first oral PCSK9 inhibitor, under the brand name Lipfendra. (a521c6b5-282b-41fc-bc6c-501153b4d97a, 8ac3ee04-3ef5-477a-9629-12a1a5039fc5, ab3f9f3c-f732-4fc8-9b8b-a178806d485f, c699e3)
[● 4 SOURCES] Enlicitide lowers LDL cholesterol by approximately 56 % to 60 % in clinical trials.
[● 4 SOURCES] Lipfendra is marketed by Merck (MSD).
[● 2 SOURCES] The pill is taken once daily on an empty stomach.
[● 2 SOURCES] The FDA approved the drug for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
[○ 1 SOURCE] Lipfendra’s list price is $315 for a 30‑day supply, cheaper than injectable PCSK9 inhibitors priced $500‑$600 per month.
[○ 1 SOURCE] Cardiovascular disease is the leading cause of death in the United States, causing about 694,708 deaths in 2025.
[○ 1 SOURCE] Only about 1 % of the roughly six million eligible patients in the U.S. currently use injectable PCSK9 inhibitors.

Timeline

2 days ago

[HEALTH] 4 sources
FDA approves Merck's oral PCSK9 inhibitor Lipfendra to lower LDL cholesterol
The FDA approved Merck's oral PCSK9 inhibitor Lipfendra (enlicitide), cutting LDL cholesterol by about 56‑60% and priced at $315/month, offering a non‑injectable alternative for high‑risk patients.
6 days ago

[HEALTH] 3 sources
FDA approves first oral PCSK9 inhibitor enlicitide to lower LDL cholesterol
The FDA approved enlicitide, the first oral PCSK9 inhibitor, cutting LDL cholesterol by up to 60% in high‑risk patients, with safety similar to placebo.
8 days ago

[HEALTH] 9 sources
FDA approves Lipfendra, first oral PCSK9 inhibitor for cholesterol
The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, reducing LDL cholesterol by up to 60% in trials and providing a new daily tablet option for adults with high cholesterol.
11 days ago

[HEALTH] 36 sources
FDA approves Merck's Lipfendra, first oral PCSK9 inhibitor for high cholesterol
The FDA approved Merck's Lipfendra, the first oral PCSK9 inhibitor, cutting LDL cholesterol by about 56‑60% and giving a pill option for high‑risk patients who previously relied on injectable drugs.

Sources

amirbolous.com · apostagem.com.br · archive.boston.com · archynewsy.com · australianpolicejournal.com.au · ballstriking.com · consultorsalud.com · csid.ro · diario.mx · diariodesalud.com.do · diariodesevilla.es · diariopernambucano.com.br · dnyuz.com · doctor33.it · easternherald.com · easycabs.com.cy · ellatinoonline.com · em.com.br · emjreviews.com · ensemblepourlaville.be · estamosaqui.mx · evianews.com · farmacista33.it · haberaktuel.com · independent.co.uk · kfgo.com · kob.com · latimes.com · libertyunyielding.com · liveblogwp.wtop.com · m.olhardigital.uol.com.br · memesita.com · metropoles.com · mindbodygreen.com · mix929.com · News18.com · nogoyatimes.com · nypost.com · oantagonista.uol.com.br · oglobo.globo.com · osul.com.br · popstaronline.com · rdmonline.com.br · sentinelcolorado.com · thelocalreport.in · thenationalpulse.com · thesheffieldpress.com · timesnownews.com

This summary has been updated 1 time: see revision history